Clinical Trials

Text Size A A

E-Mail to a Friend



secret  Click to Play Audio


Send To Friend

Providence Alaska Medical Center

Below are some of the SCCA clinical trials now being offered for patients at Providence Alaska Medical Center. If you have any questions about these or other trials, please contact Providence Alaska Medical Center.

Breast Cancer (Newly Diagnosed)

  • Pfizer Sutent (6488)
    A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer
  • Triple Negative (6628)
    Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Breast Cancer (Recurrent/Metastatic)

  • Triple Negative (6628)
    Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
  • Phase II Topical Imiquimod/wkly Abraxane (6578)
    Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases

Leukemia (Newly Diagnosed)

  • Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
    A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Leukemia (Recurrent/Metastatic)

Lymphoma (Newly Diagnosed)

  • Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
    A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Lymphoma (Recurrent/Metastatic)